Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics (DGX) filed a Form 144 reporting a proposed sale of 1,903 common shares through Fidelity Brokerage Services (900 Salem Street, Smithfield, RI) with an approximate aggregate market value of $342,540 and an indicated approximate sale date of 08/15/2025. The filing lists total shares outstanding as 111,823,441. The document also discloses a recent sale by Thomas P. Plewman of 5,535 common shares on 08/06/2025 for gross proceeds of $968,625. The record of acquisition shows numerous small purchases and vesting events (ESPP purchases, dividend reinvestments, restricted stock vesting) between 02/01/2021 and 06/28/2024 that underlie the holdings to be sold.
Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), exercised non-qualified stock options and sold shares under a Rule 10b5-1 plan on 08/06/2025. The filing shows an exercise of 3,560 options at an exercise price of $86.63 and subsequent sales of 3,560 shares at $175 and an additional 1,975 shares at $175. Following these transactions the reporting person beneficially owned 19,219 shares and the reported option grant counts are 0. The filing notes the exercise and sales were effected pursuant to a Rule 10b5-1 sales plan, that the option vested in three annual installments beginning Feb 18, 2020, and that the beneficial ownership total includes exempt purchases under the company stock purchase plan since the last Form 4.
Quest Diagnostics Inc. (DGX) has filed a Form 144 indicating an intended sale of 8,269 common shares through Fidelity Brokerage Services.
- Aggregate market value: $1,384,230.60 (based on the market price on the filing date).
- Percentage of shares outstanding: approx. 0.0074 % of the 111,823,441 shares outstanding — an immaterial level.
- Anticipated sale date: 07 / 30 / 2025 on the NYSE.
- Source of shares: options granted on 18 Feb 2019 (3,045 shares) and 18 Feb 2020 (5,224 shares); cash was paid upon exercise.
No shares were sold during the prior three months, and the signer represents no undisclosed adverse information. The filer’s name, relationship to the issuer, and 10b5-1 plan data were not disclosed in the excerpt.